|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-2.19/-0.99
|
企业价值
2.72M
|
资产负债 |
每股账面净值
-0.25
|
现金流量 |
现金流量率
--
|
损益表 |
收益
58.47K
|
每股收益
--
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/03 17:56 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology. |